Characteristics and treatments of patients enrolled in the CHAMP-HF registry compared with patients enrolled in the PARADIGM-HF trial

Journal of the American Heart Association

Volumn 7, Issue 12, 2018, Pages

  DeVore, Adam D ^a,b   Mi, Xiaojuan ^a   Thomas, Laine ^a   Sharma, Puza P ^h   Albert, Nancy M ^c   Butler, Javed ^d   Hernandez, Adrian F ^a,b   Patterson, J Herbert ^e   Spertus, John A ^f   Williams, Fredonia B ^g   Duffy, Carol I ^h   McCague, Kevin ^h   Fonarow, Gregg C ⁱ  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^e University of North Carolina   (United States)

^f UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^g Mended Hearts   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ UCLA MEDICAL CENTER   (United States)

Author keywords

Angiotensin receptor neprilysin inhibitor; Quality improvement; Registry; Sacubitril valsartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; MEMBRANE METALLOENDOPEPTIDASE; PROTEINASE INHIBITOR; TETRAZOLE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; CONVALESCENCE; DRUG EFFECT; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SELECTION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; TREATMENT OUTCOME;

AGED; AMINOBUTYRATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NEPRILYSIN; OBSERVATIONAL STUDIES AS TOPIC; PATIENT SELECTION; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; REGISTRIES; STROKE VOLUME; TETRAZOLES; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 85049137362     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.118.009237     Document Type: Article

References (13)

1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137-e161
2. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004
3. Perez AL, Kittipibul V, Tang WHW, Starling RC. Patients not meeting PARADIGM-HF enrollment criteria are eligible for sacubitril/valsartan on the basis of FDA approval: the need to close the gap. JACC Heart Fail. 2017;5:460-463
4. DeVore AD, Thomas L, Albert NM, Butler J, Hernandez AF, Patterson JH, Spertus JA, Williams FB, Turner SJ, Chan WW, Duffy CI, McCague K, Mi X, Fonarow GC. Change the management of patients with heart failure: rationale and design of the CHAMP-HF registry. Am Heart J. 2017;189:177-183
5. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014;16:817-825
6. Simpson J, Jhund PS, Silva Cardoso J, Martinez F, Mosterd A, Ramires F, Rizkala AR, Senni M, Squire I, Gong J, Lefkowitz MP, Shi VC, Desai AS, Rouleau JL, Swedberg K, Zile MR, McMurray JJV, Packer M, Solomon SD. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015;66:2059-2071
7. Pocock SJ, Ariti CA, McMurray JJV, Maggioni A, Køber L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34:1404-1413
8. Parikh KS, Lippmann SJ, Greiner M, Heidenreich PA, Yancy CW, Fonarow GC, Hernandez AF. Scope of sacubitril/valsartan eligibility after heart failure hospitalization: findings from the GWTG-HF Registry (Get With The Guidelines-Heart Failure). Circulation. 2017;135:2077-2080
9. Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, Hernandez AF, Rocha RA, Braunwald E. Rationale and design of the comparison of sacubitril/valsartan versus enalapril on effect on NT-pro-BNP in patients stabilized from an acute heart failure episode (PIONEER-HF) trial. Am Heart J. 2018;198:145-151
10. Pascual-Figal D, Wachter R, Senni M, Belohlavek J, Noé A, Carr D, Butylin D. Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan. ESC Heart Fail. 2018;5:327-336
11. Luo N, Fonarow GC, Lippmann SJ, Mi X, Heidenreich PA, Yancy CW, Greiner MA, Hammill BG, Hardy NC, Turner SJ, Laskey WK, Curtis LH, Hernandez AF, Mentz RJ, O'Brien EC. Early adoption of sacubitril/valsartan for patients with heart failure with reduced ejection fraction: insights from Get With The Guidelines-Heart Failure (GWTG-HF). JACC Heart Fail. 2017;5:305-309
12. Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington (DC): The National Academies Press; 2001. Available from: https://www.ncbi.nlm.nih.gov/books/NBK222274/doi:10.17226/10027
13. Chan WV, Pearson TA, Bennett GC, Cushman WC, Gaziano TA, Gorman PN, Handler J, Krumholz HM, Kushner RF, MacKenzie TD, Sacco RL, Smith SC Jr, Stevens VJ, Wells BL, Castillo G, Heil SK, Stephens J, Vann JC. ACC/AHA special report: clinical practice guideline implementation strategies: a summary of systematic reviews by the NHLBI implementation science work group: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135: e122-e137